The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.

Saved in:
Bibliographic Details
Title: The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Authors: Ochman AR; Melior Discovery, Inc., 860 Springdale Dr., Exton, PA 19341, USA., Lipinski CA, Handler JA, Reaume AG, Saporito MS
Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2012 Jul; Vol. 342 (1), pp. 23-32. Date of Electronic Publication: 2012 Mar 19.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1521-0103
DOI:10.1124/jpet.112.192187